Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
Citations Over TimeTop 10% of 2015 papers
Abstract
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), can attenuate tumor-associated edema and improve patient symptoms but based on magnetic resonance imaging, is associated with non-enhancing tumor progression and possibly gliosarcoma differentiation. To gain insight into these findings, we investigated the role of hypoxia and epithelial-mesenchymal transition (EMT)-associated proteins in GBM. Tumor markers of hypoxia and EMT were upregulated in bevacizumab-treated tumors from GBM patients compared to untreated counterparts. Exposure of glioma cells to 1% oxygen tension increased cell proliferation, expression of EMT-associated proteins and enhanced cell migration in vitro. These phenotypic changes were significantly attenuated by pharmacologic knockdown of hypoxia-inducible Factor 1α (HIF1α) or HIF2α, indicating that HIFs represent a therapeutic target for mesenchymal GBM cells. These findings provide insights into potential development of novel therapeutic targeting of angiogenesis-specific pathways in GBM.
Related Papers
- → Vascular endothelial growth factor B, a novel growth factor for endothelial cells.(1996)822 cited
- → Detection of Vascular Endothelial Growth Factor Messenger RNA and Vascular Endothelial Growth Factor-like Activity in Proliferative Diabetic Retinopathy(1994)363 cited
- → Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy(2012)79 cited
- → Vascular Endothelial Growth Factor (VEGF) and the VEGF Soluble Receptor-1 (sFlt-1) in Chorionic Villus Tissue from Chinese Women with Early Recurrent Spontaneous Abortion(2011)16 cited
- Comparison of Serum Concentrations of Bevacizumab and Vascular Endothelial Growth Factor (VEGF) Levels in Laser and Bevacizumab Treated ROP Patients(2014)